Wilms Tumor Mortality Statistics

What's on this page:

Learn more about Wilms tumor mortality statistics, including how many children die from Wilms tumor (nephroblastoma), the factors that influence mortality, and how death rates have changed over time as childhood cancer treatment has advanced. This comprehensive guide explores global mortality trends, differences between high-income countries (HICs) and low- and middle-income countries (LMICs), stage-specific mortality, causes of death, treatment-related mortality, relapse-associated mortality, and the impact of early diagnosis and access to specialist pediatric oncology care, helping parents, caregivers, healthcare professionals, researchers, and policymakers better understand the global burden of Wilms tumor mortality.

Mortality Rates Around the World;
HIC's Vs LMICs;
By Stage;
By Histology;
By Diagnosis
Treatment Related;
Why this Matters to Parent & Caregivers;
Frequently Asked Questions (FAQ's);
Learn More & Get Support.

Understanding Wilms Tumor Mortality Statistics

Although Wilms tumor (nephroblastoma) remains one of the greatest success stories in modern pediatric oncology, it continues to cause childhood cancer deaths around the world. Thanks to advances in surgery, chemotherapy, radiation therapy, supportive care, and international clinical research, overall survival now exceeds 90–95% in many high-income countries (HICs). This means that fewer than 5–10% of children treated in these healthcare systems die from their disease. However, mortality remains considerably higher in many low- and middle-income countries (LMICs), where overall survival may range from 40% to 70%, meaning mortality can range from 30% to more than 60%, depending on local healthcare resources and access to specialist care.

Wilms tumor mortality statistics measure the number of deaths caused by the disease and provide valuable insight into the effectiveness of healthcare systems. These statistics examine mortality according to tumour stage, histology, age at diagnosis, treatment response, relapse, healthcare access, and geographic region. They also help researchers and policymakers identify where deaths remain preventable and where investment in healthcare services can have the greatest impact.

Perhaps most importantly, mortality statistics demonstrate how dramatically outcomes have improved over time. Before modern multimodal therapy became standard practice, survival rates were below 30%, meaning most children diagnosed with Wilms tumor died. Today, more than nine out of every ten children treated in specialist centres survive long-term, making Wilms tumor one of the most curable childhood cancers.

Why Mortality Statistics Matter

Mortality statistics are among the most important indicators of childhood cancer outcomes because they measure the ultimate impact of diagnosis, treatment, supportive care, and healthcare access.

For Wilms tumor, these statistics demonstrate that the disease is highly curable when children receive timely specialist treatment. They also highlight where healthcare improvements are still needed. In many countries, deaths are now more closely associated with late diagnosis, relapse, treatment abandonment, and healthcare inequalities than with limitations of modern medical treatment itself.

Monitoring mortality trends also allows healthcare professionals to evaluate new treatment protocols, supportive care strategies, and international childhood cancer initiatives aimed at reducing preventable deaths.

Wilms Tumor Mortality Around the World

The greatest differences in mortality occur between countries with well-established pediatric oncology services and those where healthcare resources remain limited.

High-Income Countries (HICs)

Children diagnosed in countries with comprehensive childhood cancer programmes experience excellent outcomes.

Typical outcomes include:

Overall survival: 90–95%+
Mortality: Less than 5–10%
Treatment-related mortality: Usually below 2–3%
Five-year survival: Frequently greater than 90%

These excellent outcomes result from rapid diagnosis, multidisciplinary care, specialist children's hospitals, evidence-based treatment protocols, and comprehensive supportive care.

Low- and Middle-Income Countries (LMICs)

Mortality remains substantially higher across many LMICs because access to specialist childhood cancer services is often limited.

Published studies have reported:

Overall survival: 40–70%
Mortality: 30–60%+
Higher rates of delayed diagnosis.
Greater treatment abandonment.
Reduced access to surgery, chemotherapy, radiation therapy, and supportive care.

Fortunately, these figures continue to improve as healthcare systems strengthen and international collaborations expand.

Mortality by Stage at Diagnosis

The stage of disease at diagnosis remains one of the strongest predictors of mortality.

Children diagnosed with localized disease generally have an excellent prognosis, while advanced-stage disease requires more intensive treatment and carries a greater risk of relapse and death.

Stage I: 95–99% / 1–5%
Stage II: 90–95% / 5–10%
Stage III: 85–90% / 10–15%
Stage I: V70–85% / 15–30%
Stage V (bilateral): 80–90% / 10–20%

These figures vary according to tumour biology, treatment protocol, healthcare resources, and access to specialist pediatric oncology care.

Mortality by Tumour Histology

Histology is another major predictor of survival.

Approximately 90–95% of children have favourable histology Wilms tumor, which responds well to modern treatment.

Typical outcomes include:

Favourable histology: 90–95%+ / Below 10%
Diffuse anaplastic histology: 50–70% / 30–50%

Children with diffuse anaplastic Wilms tumor often require more intensive treatment because these tumours are more resistant to conventional therapy.

Causes of Mortality

Although most children survive Wilms tumor, deaths still occur for several reasons.

The leading causes include:

Progressive or treatment-resistant disease.
Relapsed Wilms tumor.
Advanced metastatic disease.
Treatment-related infections.
Organ failure during intensive therapy.
Delayed diagnosis.
Treatment abandonment.
Limited access to specialist healthcare.

Importantly, many of these causes are increasingly preventable through earlier diagnosis and improved healthcare systems.

Treatment-Related Mortality

Modern treatment is considerably safer than in previous decades.

Today:

Treatment-related mortality is generally below 2–3% in specialist centres.
Improvements in infection prevention have significantly reduced fatal complications.
Better supportive care has reduced deaths associated with chemotherapy.
Intensive care services have improved survival following severe treatment complications.

Healthcare teams continuously monitor children throughout treatment to minimise these risks.

Mortality Following Relapse

Relapse remains one of the strongest predictors of mortality.

Approximately 15–20% of children with Wilms tumor experience relapse, although rates vary depending on tumour stage and biology.

Following relapse:

Many children can still be cured using second-line therapies.
Survival after relapse generally ranges from 40–70%, depending on tumour characteristics and treatment response.
Mortality is highest among children with early relapse, diffuse anaplastic histology, or multiple relapses.

Ongoing international clinical trials continue to improve outcomes for these children.

How Mortality Has Changed Over Time

Few childhood cancers have experienced greater improvements in survival than Wilms tumor.

Historical progress includes:

Before 1960: Less than 30%
1970s: Around 60–70%
1990s: Around 80–90%
Today (specialist centres): 90–95%+

These improvements reflect decades of international clinical research, advances in surgery, chemotherapy, radiation therapy, pathology, supportive care, and multidisciplinary treatment.

Reducing Wilms Tumor Mortality

Healthcare professionals continue working to reduce mortality even further.

Strategies include:

Earlier diagnosis.
Faster referral pathways.
Improved diagnostic imaging.
Specialist pediatric oncology centres.
Modern surgical techniques.
Reliable chemotherapy supplies.
Better supportive care.
Reduced treatment abandonment.
Long-term follow-up.
International collaboration.

Many experts believe that further reductions in mortality will come primarily through improving healthcare access rather than developing entirely new treatments.

International Collaboration

Reducing childhood cancer mortality is a global priority.

Major international organisations include:

World Health Organization (WHO)
Global Initiative for Childhood Cancer (GICC)
St. Jude Children's Research Hospital
International Society of Paediatric Oncology (SIOP)
Children's Oncology Group (COG)
Childhood Cancer International (CCI)

Together these organisations support clinical research, healthcare professional education, treatment guidelines, specialist training, healthcare infrastructure, and improved access to childhood cancer services worldwide.

Understanding Wilms Tumor Mortality Statistics

Mortality statistics describe large populations rather than predicting the outcome for an individual child. Thanks to modern pediatric oncology, more than 90% of children treated in specialist centres now survive Wilms tumor. For families, these statistics provide reassurance that outcomes have improved dramatically and continue to improve each year.

For healthcare professionals and policymakers, mortality statistics identify where further investment is needed to reduce preventable deaths. Closing the survival gap between high-income and low- and middle-income countries represents one of the greatest opportunities to improve childhood cancer outcomes worldwide.

Ultimately, the continuing decline in Wilms tumor mortality reflects decades of scientific discovery, international collaboration, and improvements in healthcare delivery. As access to specialist treatment expands, more children than ever before can expect to survive and enjoy long, healthy lives after childhood cancer.

Key Facts at a Glance

Overall survival in many HICs: 90–95%+
Mortality in many HICs: Less than 5–10%
Overall survival in many LMICs: 40–70%
Mortality in many LMICs: 30–60%+
Stage I mortality: 1–5%
Stage IV mortality: 15–30%
Favourable histology mortality: Below 10%
Diffuse anaplastic mortality: 30–50%
Treatment-related mortality: Usually below 2–3%
Survival before modern treatment: Less than 30%
Survival today in specialist centres: 90–95%+

What This Means for Parents & Caregivers

Reading about Wilms tumor mortality statistics can be frightening, especially if your child has recently been diagnosed. It is natural to focus on the possibility of the worst outcome, but it is important to remember that mortality statistics describe large groups of children and do not predict what will happen to any individual child. Every child's diagnosis is unique, and your healthcare team will develop a personalised treatment plan based on your child's age, tumour stage, tumour biology, overall health, and response to treatment.

Perhaps the most reassuring message is that the vast majority of children diagnosed with Wilms tumor now survive their disease, particularly when it is diagnosed early and treated by an experienced pediatric oncology team. Thanks to decades of international research, improvements in surgery, chemotherapy, radiation therapy, supportive care, and follow-up programmes, Wilms tumor has become one of the most curable childhood cancers. Survival rates now exceed 90% in many specialist centres, giving most children the opportunity to live long, healthy, and fulfilling lives after treatment.

Although mortality has fallen dramatically, understanding why some children still die from Wilms tumor helps doctors continue improving care for future patients. Many of the factors associated with higher mortality—such as delayed diagnosis, limited access to specialist treatment, treatment abandonment, and inadequate supportive care—are increasingly being addressed through improvements in healthcare systems and international collaboration. Around the world, healthcare professionals and childhood cancer organisations are working together to ensure that more children receive timely diagnosis and life-saving treatment.

Parents and caregivers play an important role in helping achieve the best possible outcome for their child. Recognising symptoms early, attending appointments, following the recommended treatment plan, reporting side effects promptly, and maintaining close communication with the healthcare team all contribute to successful treatment. You are an essential member of your child's care team, and your involvement helps healthcare professionals provide the safest and most effective care possible.

Parents and caregivers can help support the best possible outcome by:

Seeking medical assessment promptly if symptoms suggest Wilms tumor or another childhood cancer.
Attending all appointments, investigations, and treatment sessions throughout your child's care.
Following your child's treatment plan carefully, including medications and follow-up visits.
Reporting new symptoms, side effects, or concerns immediately so they can be managed quickly.
Asking questions whenever you are uncertain about any aspect of your child's diagnosis or treatment.
Seeking practical and emotional support from your healthcare team, social workers, charities, parent support groups, and community organisations whenever needed.

Families living in low- and middle-income countries (LMICs) may experience additional challenges accessing specialist childhood cancer services. International organisations such as the World Health Organization (WHO), the Global Initiative for Childhood Cancer (GICC), St. Jude Children's Research Hospital, the International Society of Paediatric Oncology (SIOP), and many national childhood cancer programmes are working to reduce these inequalities by improving healthcare infrastructure, expanding specialist treatment services, training healthcare professionals, and supporting families throughout treatment.

Perhaps the most important message is one of hope. Mortality from Wilms tumor has fallen dramatically over recent decades because of advances in medical science and international collaboration. Every year, more children survive than ever before, and ongoing research continues to improve treatments while reducing complications. While a diagnosis of childhood cancer is undoubtedly overwhelming, today's treatments offer excellent prospects for recovery for most children, and healthcare teams around the world remain committed to improving outcomes even further.

Frequently Asked Questions (FAQs)

About Willms Tumor Mortality Rates

What is the mortality rate for Wilms tumor?

The mortality rate for Wilms tumor (nephroblastoma) varies depending on where a child receives treatment and several clinical factors, including tumour stage and histology. In many high-income countries (HICs), overall survival exceeds 90–95%, meaning that fewer than 5–10% of children die from the disease. In some low- and middle-income countries (LMICs), mortality remains significantly higher because of delayed diagnosis, limited access to specialist care, treatment abandonment, and healthcare resource limitations.

Has mortality from Wilms tumor improved over time?

Yes. Mortality from Wilms tumor has declined dramatically over the past several decades. Before modern treatment became available, survival was less than 30%, meaning most children died from the disease. Today, advances in surgery, chemotherapy, radiation therapy, supportive care, and international research have increased survival to more than 90% in many specialist treatment centres.

What factors increase the risk of dying from Wilms tumor?

Several factors can increase mortality, including:

Advanced-stage disease at diagnosis.
Diffuse anaplastic histology.
Relapsed or treatment-resistant disease.
Delayed diagnosis.
Treatment abandonment.
Limited access to specialist pediatric oncology services.
Severe treatment complications.
Incomplete treatment.

Early diagnosis and timely specialist care significantly improve the chances of survival.

Does the stage of Wilms tumor affect mortality?

Yes. The stage of the tumour is one of the strongest predictors of outcome. Children diagnosed with Stage I or Stage II Wilms tumor generally have survival rates exceeding 90–95%, while children with Stage IV disease face a higher risk of relapse and mortality. Despite this, many children with advanced-stage disease are still successfully treated using modern therapies.

Does tumour histology affect mortality?

Yes. Approximately 90–95% of children have favourable histology Wilms tumor, which responds well to treatment and has excellent survival rates. Diffuse anaplastic Wilms tumor, which accounts for around 5–10% of cases, is more aggressive and is associated with a higher risk of treatment failure, relapse, and mortality.

Can children survive after Wilms tumor relapses?

Yes. Although relapse increases the risk of mortality, many children can still be successfully treated. Survival after relapse depends on factors such as the timing of recurrence, tumour biology, previous treatments, and response to second-line therapy. Ongoing international clinical trials continue to improve outcomes for children with relapsed Wilms tumor.

What is treatment-related mortality?

Treatment-related mortality refers to deaths caused by complications of cancer treatment rather than the tumour itself. These complications may include severe infections, organ failure, or other serious side effects. In specialist pediatric oncology centres, treatment-related mortality is now uncommon, generally affecting less than 2–3% of children, thanks to advances in supportive care and careful monitoring.

Why is mortality higher in some countries?

Children living in low- and middle-income countries (LMICs) often face greater challenges accessing specialist childhood cancer care. Delayed diagnosis, shortages of healthcare professionals, limited availability of medicines, treatment abandonment, financial barriers, and weaker healthcare infrastructure all contribute to higher mortality. International partnerships are helping many countries improve access to treatment and reduce these inequalities.

How are international organisations helping reduce Wilms tumor mortality?

Several international organisations are working to improve survival and reduce childhood cancer deaths worldwide, including:

World Health Organization (WHO).
Global Initiative for Childhood Cancer (GICC).
St. Jude Children's Research Hospital.
International Society of Paediatric Oncology (SIOP).
Children's Oncology Group (COG).
Childhood Cancer International (CCI).

These organisations support clinical research, healthcare professional training, treatment guidelines, healthcare system strengthening, and improved access to specialist pediatric oncology services.

What can parents do to improve their child's chances of survival?

Parents and caregivers play an important role by seeking medical assessment promptly if symptoms develop, attending all appointments, following the recommended treatment plan, reporting side effects early, maintaining regular communication with the healthcare team, and completing all stages of treatment and follow-up care. Early diagnosis and treatment completion provide the best opportunity for a successful outcome.

Is Wilms tumor still considered one of the most curable childhood cancers?

Yes. Wilms tumor is widely regarded as one of the most curable childhood cancers. In countries with access to specialist pediatric oncology care, more than nine out of every ten children survive their disease. Continued advances in research and international collaboration are expected to improve outcomes even further in the coming years.

Where can I learn more about Wilms tumor survival and treatment outcomes?

You can explore our related resources covering:

Overall Survival Statistics
Treatment Success Statistics
Long-Term Survivorship Statistics
Relapse Statistics
Treatment Abandonment Statistics
Pediatric Oncology Access Statistics
Healthcare Systems, Health Equity & Global Childhood Cancer Policy
Global Disease Burden
WHO Global Initiative for Childhood Cancer (GICC)
International Childhood Cancer Partnerships

These evidence-based resources explain how advances in pediatric oncology, international collaboration, and improved healthcare access continue to reduce mortality and improve outcomes for children diagnosed with Wilms tumor worldwide.

More about Wilms Tumor Statistics

Wilms Tumor Survival Statistics

Learn how modern treatments have improved survival rates for children diagnosed with Wilms tumor and the factors influencing long-term outcomes.

Survival Statistics After Relapse

Explore survival outcomes following relapsed Wilms tumor and the treatments helping improve recovery after recurrent childhood kidney cancer.

Global Wilms Tumor Statistics

Explore global Wilms tumor statistics, childhood kidney cancer incidence, survival disparities, access to treatment, and worldwide pediatric oncology data relating to nephroblastoma and childhood cancer care.

Childhood Cancer Statistics

Compare childhood cancer statistics worldwide and understand where Wilms tumor fits within the global pediatric cancer landscape.

Wilms Tumor Relapse Statistics

Learn how often Wilms tumor returns after treatment and the factors influencing the risk of recurrence.

Stage-Based Survival Statistics

Explore how survival rates vary according to Wilms tumor stage and why early diagnosis significantly improves outcomes.